NuCana is trading 12.5% higher at $1.17, with broader biotech strength offering context but no confirmed direct cause. - No company-specific announcement explaining the move surfaced in news search for October 27, 2026; a market research page also reported no headlines for the date. - The supplied sector update showed XBI up 2.18%, amid positive clinical-trial and regulatory news across other companies. - NuCana gained 5.55% at the October 26 close, before today’s larger live move.